A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Hans C. Lee; Jatin J. Shah; Lei Feng; Ashley Morphey; Ralph J. Johnson; Emily T. Wesson; Michael L. Wang; Raymond Alexanian; Sheeba K. Thomas; Robert Z. Orlowski; Donna M. Weber

doi:10.1002/ajh.25633

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Hans C. Lee, Jatin J. Shah, Lei Feng, Ashley Morphey, Ralph J. Johnson, Emily T. Wesson, Michael L. Wang, Raymond Alexanian, Sheeba K. Thomas, Robert Z. Orlowski, Donna M. Weber

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	E319-E322
Journal	American journal of hematology
Volume	94
Issue number	12
DOIs	https://doi.org/10.1002/ajh.25633
State	Published - Dec 1 2019

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25633

Cite this

Lee, H. C., Shah, J. J., Feng, L., Morphey, A., Johnson, R. J., Wesson, E. T., Wang, M. L., Alexanian, R., Thomas, S. K., Orlowski, R. Z., & Weber, D. M. (2019). A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. American journal of hematology, 94(12), E319-E322. https://doi.org/10.1002/ajh.25633

@article{d324892e84124c0c997bf62952882b71,

title = "A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma",

author = "Lee, {Hans C.} and Shah, {Jatin J.} and Lei Feng and Ashley Morphey and Johnson, {Ralph J.} and Wesson, {Emily T.} and Wang, {Michael L.} and Raymond Alexanian and Thomas, {Sheeba K.} and Orlowski, {Robert Z.} and Weber, {Donna M.}",

note = "Funding Information: R.Z.O. has received consulting fees from Amgen Inc, Bristol‐Myers‐Squibb, Celgene Inc, Janssen Pharmaceutical, Kite Pharma, Sanofi and Takeda Pharmaceutical and research support from Amgen Inc, BioTheryX and Spectrum Pharmaceuticals. Funding Information: S.K.T. has received consulting fees from Amgen Inc. and research support from Acerta Pharma, Amgen Inc., Array BioPharma, Bristol‐Myers‐Squibb, Celgene Inc., and Idera Inc. Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). H.C.L. would like to acknowledge support from the Baer Family Fund and Goff-Street Foundation. The authors would like to thank members of the MD Anderson Plasma Cell Dyscrasias Clinical Research Team including Marcus Austin, Brandon Crumpton, Maureen Daily, Claudia Morales de Partovi, Jasper Olsem, Kinishia Smith, Amishi Vora, and Kathleen Wall for providing study support with data collection and management. Funding Information: H.C.L. has received consulting fees from Amgen Inc, Celgene Inc., Janssen Pharmaceutical, and Takeda Pharmaceutical and research support from Amgen Inc, Celgene Inc., Daiichi Sankyo, Janssen Pharmaceutical, and Takeda Pharmaceutical. ",

year = "2019",

month = dec,

day = "1",

doi = "10.1002/ajh.25633",

language = "English (US)",

volume = "94",

pages = "E319--E322",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

AU - Lee, Hans C.

AU - Shah, Jatin J.

AU - Feng, Lei

AU - Morphey, Ashley

AU - Johnson, Ralph J.

AU - Wesson, Emily T.

AU - Wang, Michael L.

AU - Alexanian, Raymond

AU - Thomas, Sheeba K.

AU - Orlowski, Robert Z.

AU - Weber, Donna M.

N1 - Funding Information: R.Z.O. has received consulting fees from Amgen Inc, Bristol‐Myers‐Squibb, Celgene Inc, Janssen Pharmaceutical, Kite Pharma, Sanofi and Takeda Pharmaceutical and research support from Amgen Inc, BioTheryX and Spectrum Pharmaceuticals. Funding Information: S.K.T. has received consulting fees from Amgen Inc. and research support from Acerta Pharma, Amgen Inc., Array BioPharma, Bristol‐Myers‐Squibb, Celgene Inc., and Idera Inc. Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). H.C.L. would like to acknowledge support from the Baer Family Fund and Goff-Street Foundation. The authors would like to thank members of the MD Anderson Plasma Cell Dyscrasias Clinical Research Team including Marcus Austin, Brandon Crumpton, Maureen Daily, Claudia Morales de Partovi, Jasper Olsem, Kinishia Smith, Amishi Vora, and Kathleen Wall for providing study support with data collection and management. Funding Information: H.C.L. has received consulting fees from Amgen Inc, Celgene Inc., Janssen Pharmaceutical, and Takeda Pharmaceutical and research support from Amgen Inc, Celgene Inc., Daiichi Sankyo, Janssen Pharmaceutical, and Takeda Pharmaceutical.

PY - 2019/12/1

Y1 - 2019/12/1

UR - http://www.scopus.com/inward/record.url?scp=85073921981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073921981&partnerID=8YFLogxK

U2 - 10.1002/ajh.25633

DO - 10.1002/ajh.25633

M3 - Letter

C2 - 31489991

AN - SCOPUS:85073921981

SN - 0361-8609

VL - 94

SP - E319-E322

JO - American journal of hematology

JF - American journal of hematology

IS - 12

ER -

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this